The Journal of Allergy and Clinical Immunology
Volume 114, Issue 6 , Pages 1353-1358 , December 2004

Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides

  • Noritaka Higashi, MD, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • Third Department of Internal Medicine, Kagoshima University School of Medicine, Sakuragaoka, Kagoshima
    • Corresponding Author InformationReprint requests: Noritaka Higashi, MD, Scheeles väg1, PO Box 287, National Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
    • ,
  • Haruhisa Mita, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • ,
  • Masami Taniguchi, MD, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • ,
  • Naomi Turikisawa, MD, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • ,
  • Ai Higashi, MD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • Third Department of Internal Medicine, Kagoshima University School of Medicine, Sakuragaoka, Kagoshima
    • ,
  • Yoshinori Ozawa, MD, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • ,
  • Shigeto Tohma, MD, PhD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa
    • ,
  • Kimiyoshi Arimura, MD, PhD

      Affiliations

    • Third Department of Internal Medicine, Kagoshima University School of Medicine, Sakuragaoka, Kagoshima
    • ,
  • Kazuo Akiyama, MD

      Affiliations

    • From the Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa

Received 23 April 2004 ,Revised 3 August 2004 ,Accepted 20 September 2004.

References 

  1. Jong EC, Henderson WR, Klebanoff SJ. Bactericidal activity of eosinophil peroxidase. J Immunol. 1980;124:1378–1382
  2. Ten RM, Pease LR, McKean DJ, Bell MP, Gleich GJ. Molecular cloning of the human eosinophil peroxidase: evidence for the existence of a peroxidase multigene family. J Exp Med. 1989;169:1757–1769
  3. Sakamaki K, Tomonaga M, Tsukui K, Nagata S. Molecular cloning and characterization of a chromosomal gene for human eosinophil peroxidase. J Biol Chem. 1989;264:16828–16836
  4. Carlson MG, Peterson CG, Venge P. Human eosinophil peroxidase: purification and characterization. J Immunol. 1985;134:1875–1879
  5. Klebanoff SJ, Locksley RM, Jong EC, Rosen H. Oxidative response of phagocytes to parasite invasion. Ciba Found Symp. 1983;99:92–112
  6. Weiss SJ, Test ST, Eckmann CM, Roos D, Regiani S. Brominating oxidants generated by human eosinophils. Science. 1986;234:200–203
  7. Thomas EL, Bozeman PM, Jefferson MM, King CC. Oxidation of bromide by the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase: formation of bromamines. J Biol Chem. 1995;270:2906–2913
  8. Wu W, Chen Y, d'Avignon A, Hazen SL. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry. 1999;38:3538–3548
  9. Podrez EA, Abu-Sound HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000;28:1717–1725
  10. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils: evidence for hypochlorous acid generation. J Clin Invest. 1982;70:598–607
  11. Foote CS, Goyne TE, Lehrer RI. Assessment of chlorination by human neutrophils. Nature. 1983;301:715–716
  12. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human neutrophils employ chloride gas as an oxidant during phagocytosis. J Clin Invest. 1996;98:1283–1289
  13. Wu W, Samoszuk MK, Comhair SA, Thomassen MJ, Farver CF, Dweik RA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest. 2000;105:1455–1463
  14. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine. 1984;63:65–81
  15. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine. 1999;78:26–37
  16. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;35:921–930
  17. Schmitt WH, Csernok E, Kobayashi S, Klinkenborg A, Reinhold-Keller E, Gross WL. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum. 1998;41:445–452
  18. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075–2081
  19. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425–429
  20. Falk RJ, Jenette JC. Anti-neutrophil cytoplasmic antibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescenteric glomerulonephritis. N Engl J Med. 1988;318:1651–1657
  21. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999;111:507–513
  22. Sundy JS, Haynes BF. Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am. 1995;21:861–881
  23. Mayatepek E, Lehmann WD. Increased generation of cysteinyl leukotrienes in Kawasaki disease. Arch Dis Child. 1995;72:526–527
  24. Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol. 2001;108:175–183
  25. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–1100
  26. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitis: proposal of an International Consensus Conference. Arthritis Rheum. 1994;37:187–192
  27. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004;92:80–87
  28. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1101–1107
  29. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–1128
  30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324
  31. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentration in sputum and urine in the patients with aspirin-intolerant asthma. Clin Exp Allergy. 2002;32:1484–1490
  32. Mita H, Higashi N, Taniguchi M, Higashi A, Kawagishi Y, Akiyama K. Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after aspirin challenge. Clin Exp Allergy. 2004;34:931–938
  33. Frost MT, Halliwall B, Moore KP. Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/mass spectrometry method that avoids nitration artifacts. Biochem J. 2000;345:453–458
  34. Gaut JP, Byun J, Tran HD, Heinecke JW. Artifact-free quantification of free 3-chlorotyrosine, bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem. 2002;300:252–259
  35. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy. 1997;52:124–135
  36. Sjöström M, Jakobsson PJ, Heimburger M, Palmblad J, Haeggström JZ. Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the CysLT1 receptor. Eur J Biochem. 2001;268:2578–2586
  37. Sampson AP. Leukotrienes in cardiovascular disease. Clin Exp Allergy Rev. 2001;1:170–174
  38. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4: impact of aspirin therapy. Circulation. 1992;86:56–63
  39. Szczeklik A, Nizankowska E, Mastalerz L, Bochenek G. Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol. 2002;109:572–573
  40. Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishii T, Higashi A, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2004;113:277–283
  41. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis and management. J Allergy Clin Immunol. 2003;111:913–921
  42. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113:771–775
  43. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989–990
  44. MacPherson JC, Comhair SA, Erzurum SC, Klein DF, Lipscomb MF, Kavuru MS, et al. Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol. 2001;166:5763–5772
  45. Aldridge RE, Chan T, van Dalen CJ, Senthilmohan R, Winn M, Venge P, et al. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic Biol Med. 2002;33:847–856
  46. Holgate ST. The epidemic of allergy and asthma. Nature. 1999;402:B2–B4
  47. Weller PF. Eosinophils: structure and functions. Curr Opin Immunol. 1994;6:85–90
  48. Sato E, Camhi SL, Koyama S, Robbins RA. Methotrexate stimulates lung fibroblasts and epithelial cells to release eosinophil chemotactic activity. J Rheumatol. 2001;28:502–508
  49. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease, part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–340
  50. Evereklioglu C, Özbek E, Çekmen M, Mehmet N, Duygulu N, Ozkiris A, et al. Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behçet's disease: is it a new urinary activity marker?. Nephrology (Carlton). 2003;8:231–238
  51. Mani AR, Pannala AS, Orie NN, Ollosson R, Harry D, Rice-Evans CA, et al. Nitration of endogenous para-hydroxyphenylacetic acid and the metabolism of nitrotyrosine. Biochem J. 2003;374:521–527

PII: S0091-6749(04)02482-0

doi: 10.1016/j.jaci.2004.09.027

The Journal of Allergy and Clinical Immunology
Volume 114, Issue 6 , Pages 1353-1358 , December 2004

Article Tools

* Image Usage & Resolution